In this "Medical Minute" segment, medical analyst Dr. Ford Vox discusses the crisis in drug costs and a new factor in the debate over what consumers should be paying.
Researchers are trying to conduct independent analyses of a drug company’s true expenses on the road to FDA approval. In the latest analysis, the research and development numbers fell far short of industry claims.
For more information:
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Internal Medicine.